Skip to main content

Table 4 Questionnaire-based outcome means at baseline

From: Collaborative care for depression and anxiety disorders: results and lessons learned from the Danish cluster-randomized Collabri trials

 

Depression trial

Pooled anxiety trial

CC (n = 272)

TAU (n = 53)

CC (n = 369)

TAU (n = 37)

BDI-II

28.4 (27.2–29.6)

27.8 (25.0–30.6)

18.1 (17.0–19.3)

18.1 (15.0–21.1)

BAI

17.5 (16.3–18.7)

17.9 (15.1–20.7)

21.8 (20.8–22.8)

21.2 (17.9–24.6)

SCL-90-Ra

109.4 (103.2–115.7)

102.6 (87.2–117.9)

87.8 (81.9–93.6)

83.1 (62.9–103.2)

GAF

53.3 (51.9–54.8)

52.5 (49.5–55.5)

60.4 (59.3–61.6)

60.1 (57.0–63.2)

The Diagnostic Apathia Scale

8.4 (8.1–8.8)

8.8 (8.1–9.5)

5.9 (5.6–6.3)

5.9 (4.9–7.0)

PSP

55.9 (54.6–57.3)

53.8 (50.8–56.8)

62.3 (61.1–63.4)

62.0 (59.0–65.0)

SDS

18.3 (17.5–19.1)

16.3 (14.3–18.2)

13.5 (12.6–14.3)

14.3 (11.4–17.2)

WHO-5

22.2 (20.3–24.1)

24.0 (19.6–28.4)

34.9 (32.7–37.1)

35.9 (27.7–44.1)

Personal Controlb

20.3 (19.8–20.8)

20.0 (19.1–20.8)

20.6 (20.2–21.0)

21.8 (20.5–23.1)

Control/Manage Depressionc

4.4 (4.2–4.6)

4.7 (4.2–5.3)

5.6 (5.4–5.8)

5.4 (4.7–6.1)

Obtain Help from Community, Family, Friendsc

5.8 (5.5–6.0)

5.4 (4.9–6.0)

6.5 (6.3–6.7)

6.8 (6.1–7.6)

EQ-5D-3 L

0.6 (0.6–0.7)

0.6 (0.6–0.7)

0.7 (0.7–0.7)

0.7 (0.6–0.7)

PRISEd

20.6 (19.1–22.1)

18.3 (14.9–21.8)

21.3 (19.4–23.2)

20.7 (15.0–26.3)

  1. Abbreviations: BDI-II Beck Depression Inventory-II, BAI Beck Anxiety Inventory, CC Collaborative care, CSQ-8 Client Satisfaction Questionnaire, GAF-F Global Assessment of Functioning, EQ-5D-3L EuroQol Five Dimensions Questionnaire with Three Levels, PSP Personal and Social Performance Scale, PRISE Patient Rated Inventory of Side Effects, SCL-90-R Symptom Checklist-90-Revised, SDS Sheehan Disability Scale, TAU Treatment-as-usual, WHO-5 World Health Organization-5 Well-Being Index
  2. Note: Means are based on observed cases and can vary from the total numbers indicated in the column headings. No statistically significant differences between groups were found, except for SDS in the depression trial (p = 0.046). In BDI-II, BAI, SCL-90-R, SDS, The Diagnostic Apathia Scale, and PRISE, lower scores are associated with a better outcome. In GAF, PSP, WHO-5, Personal control subscale from IPQ-R, Control/manage Depression subscale, Obtain Help from Community, Family, Friends subscale, and EQ-5D-3L higher scores are associated with a better outcome
  3. a SCL-90-R was modified slightly as a reference period of two weeks was used instead of one week. b Subscale from the Illness Perception Questionnaire-Revised (IPQ-R). c Subscale from the Chronic Disease Self-Efficacy Scales. d Side effects were reported for the proportion of participants who used medication